Search Results
Your search for Caroline Helwick,Caroline Helwick matches 2415 pages
Showing 601 - 650Adoptive Cell Therapy May Soon Be Available for Patients With Melanoma
Oncologists who treat patients with melanoma will need to become familiar with another immunotherapy approach. For refractory metastatic disease, adoptive cell therapy is on the horizon. “Adoptive cell therapy will offer additional hope for our patients with melanoma. We’ll likely be seeing this...
ASCO 2021: Roundup of Studies You May Have Missed
As ASCO Annual Meeting attendees know by now, clinicians don’t have to be at McCormick Place to hear practice-changing findings and forward-looking advances in the field of oncology. Interesting content was no exception at the 2021 conference, so in addition to covering the biggest news from the...
Lymphoid Malignancies: What’s Next for Antibody-Drug Conjugates?
Antibody-drug conjugates are improving outcomes of patients with lymphoma, often those who have exhausted treatment options after chimeric antigen receptor (CAR) T-cell therapy. Four available antibody-drug conjugates are in the clinic, with brentuximab vedotin moving into the front-line...
Putting Radiotherapy to Best Use With CAR T-Cell Therapy in Lymphoma
The integration of radiation therapy into chimeric antigen receptor (CAR) T-cell therapy may improve outcomes for patients with relapsed or refractory lymphoma, according to Charles A. Enke, MD, Professor and the Bill Bures and Jerry Pabst Chair in Radiation Oncology at the Fred and Pamela Buffett...
Bispecific Antibodies Find a Place in B-Cell Lymphoma Treatment
In relapsed or refractory B-cell lymphomas, bispecific T-cell engager antibodies are finding a place in the treatment algorithm, said Christopher Flowers, MD, MS, FASCO, Professor and Chair of the Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center, Houston. At the...
Expert Point of View: Elena Élez, MD, PhD
Invited discussant of the two studies, Elena Élez, MD, PhD, of the Colon Cancer Program, Vall d’Hebron Institute of Oncology, Barcelona, Spain, discussed the challenge of treating BRAF-mutant colorectal cancer and what the new data bring to that effort. Dr. Élez noted: “BRAF V600E–mutant metastatic ...
BRAF-Mutant Colorectal Cancer: Latest Findings for Targeted Treatment
The phase II ANCHOR CRC study, the largest prospective study of BRAF inhibitor–based therapy as first-line treatment of metastatic colorectal cancer, has met its primary endpoint, with 47.8% of patients with metastatic colorectal cancer responding to first-line treatment with encorafenib,...
DESTINY Breast03: Second-Line Fam-Trastuzumab Deruxtecan-nxki for Metastatic HER2-Positive Breast Cancer
Fam-trastuzumab deruxtecan-nxki (T-DXd) showed statistically significant improvement in progression-free survival vs trastuzumab emtansine (T-DM1) in second-line treatment for HER2-positive unresectable or metastatic breast cancer, according to results from the global phase III DESTINY-Breast03...
DESTINY-Gastric02: Fam-Trastuzumab Deruxtecan-nxki Produces Responses in Patients With HER2-Positive Gastric Cancers
In the primary analysis of the phase II DESTINY-Gastric02 trial, fam-trastuzumab deruxtecan-nxki (T-DXd) produced clinically meaningful and durable responses in Western patients with advanced HER2-positive gastric or gastroesophageal junction cancers whose disease had progressed after a...
Phase III Trial Investigates Extended Adjuvant Endocrine Therapy for Postmenopausal Patients With Breast Cancer
For patients with early-stage hormone receptor–positive breast cancer, extending the duration of letrozole after tamoxifen—for up to 8 years of total endocrine therapy—significantly improved invasive disease–free survival and overall survival over the standard treatment of approximately 5 years of...
Atezolizumab Plus Chemotherapy in Patients With Advanced NSCLC and Brain Metastases
Patients with advanced non–small cell lung cancer (NSCLC) and brain metastases derived benefit from treatment with atezolizumab plus chemotherapy, according to findings from the multicenter phase II ATEZO-BRAIN/GECP 17/05 trial. The study was presented at the International Association for the Study ...
Neoadjuvant Atezolizumab Under Study for Resectable Pleural Mesothelioma
Neoadjuvant atezolizumab combined with pemetrexed and cisplatin, followed by surgical resection and maintenance atezolizumab, proved safe and feasible and offered hints of benefit in patients with resectable pleural mesothelioma. Results from a small multicenter study were presented by Boris...
IMpower010 Study of Atezolizumab in Resectable NSCLC: Benefits Observed Regardless of Stage, Type of Prior Treatment
In an exploratory analysis of the pivotal phase III IMpower010 trial—which found that adjuvant atezolizumab significantly improved disease-free survival in resectable non–small cell lung cancer (NSCLC)—benefit was shown regardless of the type of surgery or the chemotherapy doublet received by the...
No Overall Survival Benefit With Lurbinectedin/Doxorubicin in Small Cell Lung Cancer
As a second-line treatment for patients with small cell lung cancer (SCLC), lurbinectedin plus doxorubicin failed to improve overall survival in the multicenter ATLANTIS trial, but it did provide other benefits, Luis Paz-Ares, MD, PhD, and colleagues reported at the International Association for...
Evandro de Azambuja, MD, PhD, Comments on the BERENICE Trial
The invited discussant for the BERENICE trial was Evandro de Azambuja, MD, PhD, Head of the Medical Support Team at the Institut Jules Bordet in Brussels. He concluded from the study that pertuzumab plus trastuzumab, combined with an anthracycline/taxane regimen given every 2 weeks or every 3...
Safety, Efficacy of Neoadjuvant Pertuzumab Plus Trastuzumab Maintained in Final Analysis of BERENICE Trial
Long-term cardiac safety and efficacy have been confirmed for pertuzumab plus trastuzumab in patients with early breast cancer, in an update of the phase II BERENICE trial reported at the 2021 ESMO Breast Cancer Virtual Congress.1 Chau T. Dang, MD, of the Breast Medicine Service at Memorial Sloan...
Are Triplets Necessary for BRAF-Mutated Melanoma?
Where does triplet therapy fit in the treatment of patients with stage IV BRAF-mutated melanoma? Is there strong evidence for combining a BRAF inhibitor, MEK inhibitor, and checkpoint inhibitor? Ragini Kudchadkar, MD, Chair of the Protocol Review and Monitoring Committee at Winship Cancer Institute ...
Prostate Cancer Diagnostics: Novel Approaches Are Leaving Conventional Imaging Behind
Advances in molecular imaging are having a big impact on prostate cancer management and outcomes, according to Ashesh B. Jani, MD, the James C. Kennedy Professor in Prostate Cancer, Department of Radiation Oncology at the Winship Cancer Institute of Emory University, Atlanta. Dr. Jani described his ...
Liquid Biopsy Is Changing Colon Cancer Management
The measurement of circulating tumor DNA (ctDNA) is changing the way gastrointestinal cancers are managed, according to Bassel F. El-Rayes, MD, Professor and Vice Chair for Clinical Research in the Department of Hematology and Oncology, Emory University, and Associate Cancer Center Director,...
Axicabtagene Ciloleucel Improves Multiple Clinical Endpoints in Relapsed Follicular Lymphoma
For the treatment of relapsed or refractory follicular lymphoma, updated data from the ZUMA-5 trial, as compared with the findings of the external control cohort of SCHOLAR-5, showed substantial improvement in all key clinical endpoints with axicabtagene ciloleucel, ZUMA-5 investigators reported in ...
Outcomes Notably Improving for Adult ALL
Outcomes in adults with acute lymphoblastic leukemia (ALL) are almost rivaling those in pediatric ALL, thanks to the benefits achieved by incorporating blinatumomab and inotuzumab into chemotherapy regimens. New ways of administering the chemotherapy component are also increasing tolerability and...
Eric Deutsch, MD, PhD, Comments on the Averectal and AVANA Trials in Rectal Cancer
Eric Deutsch, MD, PhD, Professor and Chair of Radiation Oncology at Gustave Roussy, Villejuif, France, commended the speakers for conducting trials whose results he found “very interesting.” The Averectal trial involved a short course of radiation with modified FOLFOX-6 (oxaliplatin, fluorouracil...
Avelumab Under Study as Adjunct to Neoadjuvant Therapy for Rectal Cancer
In the treatment of newly diagnosed locally advanced rectal cancer, two phase II studies evaluating the addition of the PD-L1 inhibitor avelumab to chemoradiotherapy showed promising rates of pathologic complete response, major pathologic response, and tumor downstaging. The study investigators...
Tackling the Challenge of Pancreatic Cancer: New Approaches
Pancreatic cancer remains an incorrigible foe, but recent advances in genomic profiling and targeted drug development are slowly improving the outlook for patients, according to Eileen M. O’Reilly, MD, Winthrop Rockefeller Endowed Chair in Medical Oncology and Section Head,...
Expert Point of View: Nicole Chau, MD
ASCO discussant Nicole Chau, MD, Clinical Associate Professor at the University of British Columbia/BC Cancer in Vancouver, said the COSMIC-311 trial was “noteworthy for meeting its co-primary endpoint of progression-free survival (hazard ratio = 0.22) in this heavily pretreated patient...
Cabozantinib: Potential New Option for Treatment-Refractory Thyroid Cancer
The tyrosine kinase inhibitor cabozantinib appears to be an effective new option for treatment-refractory differentiated thyroid cancer, according to the phase III COSMIC-311 trial, which was stopped early for efficacy.1 COSMIC-311 is the first randomized placebo-controlled trial to evaluate the...
Expert Point of View: Melinda L. Telli, MD
The invited discussant of GeparNuevo,1 Melinda L. Telli, MD, Associate Professor of Medicine at Stanford University School of Medicine, Director of the Breast Cancer Program at the Stanford Cancer Institute, and Associate Director of the Stanford Women’s Cancer Center, welcomed the additional data...
Neoadjuvant Durvalumab Improves Long-Term Outcomes in the GeparNuevo Trial
In the phase II GeparNuevo trial, patients with early triple-negative breast cancer receiving the PD-L1 inhibitor durvalumab in addition to chemotherapy as neoadjuvant therapy saw improvements in long-term outcomes. The results were presented at the 2021 ASCO Annual Meeting by Sibylle Loibl, MD,...
Expert Point of View: Leslie Popplewell, MD
“Naratuximab emtansine plus rituximab appears to be an effective and well tolerated combination in a heavily pretreated population. The results of the study are very promising,” said Leslie Popplewell, MD, Associate Clinical Professor, Department of Hematology and Hematopoietic Cell...
Novel Antibody-Drug Conjugate Under Study in Refractory DLBCL
The combination of the CD37-targeting antibody-drug conjugate naratuximab emtansine and rituximab yielded deep and long-lasting responses in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), in a phase II trial presented during the 2021 European Hematology Association...
Expert Point of View: Jacqueline C. Barrientos, MD, MS
The ASCO Post invited Jacqueline C. Barrientos, MD, MS, Associate Professor of Medicine, CLL Research and Treatment Program, Zucker School of Medicine at Hofstra/Northwell, Lake Success, New York, to comment on the ALPINE findings presented at the European Hematology Association (EHA) Virtual...
Zanubrutinib Superior to Ibrutinib for CLL/SLL in Phase III ALPINE Trial
Zanubrutinib, a second-generation Bruton’s tyrosine kinase (BTK) inhibitor, significantly improved response rates and delayed disease progression as compared with the standard of care, ibrutinib, in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma...
Expert Point of View: Kei Muro, MD, PhD
The RATIONALE 302 trial1 was discussed by Kei Muro, MD, PhD, of Aichi Cancer Center Hospital in Nagoya, Japan, who found the results promising. However, Dr. Muro questioned the role of PD-1/L1 inhibitors as second-line therapy for advanced esophageal squamous cell carcinoma. RATIONALE 302 is the...
RATIONALE 302: Tislelizumab Improves Overall Survival as Second-Line Treatment of Esophageal Cancer
In the phase III RATIONALE 302 trial, the novel anti–PD-1 antibody tislelizumab, being developed in China, improved overall survival vs chemotherapy as second-line therapy for esophageal squamous cell carcinoma, according to Jaffer Ajani, MD, of The University of Houston MD Anderson Cancer Center,...
Expert Point of View: Thomas Seufferlein, MD, PhD
The invited discussant of APACT,1 Thomas Seufferlein, MD, PhD, Professor of Medicine at the University of Ulm in Germany, said the updated overall survival data “suggest an improved outcome with nab-paclitaxel plus gemcitabine vs gemcitabine alone…. The combination improves long-term survival and...
APACT: 5-Year Overall Survival Data Suggest Improved Outcomes in Pancreatic Cancer With Nab-paclitaxel/Gemcitabine
The 5-year outcomes in the APACT trial uphold the overall survival benefit with nab-paclitaxel plus gemcitabine in the adjuvant treatment of patients with resected pancreatic cancer, according to Margaret A. Tempero, MD, Director of the University of California San Francisco Pancreas Center, who...
Expert Point of View: Chris Verslype, MD, PhD
The invited discussant of the RATIONALE 208 trial, Chris Verslype, MD, PhD, Professor of Medicine at University Hospitals Leuven in Belgium, said tislelizumab is an “active and safe” investigational PD-1 antibody, “comparable to other PD-1 agents.” In particular, he noted, the results of RATIONALE ...
RATIONALE 208: ‘Durable Clinical Activity’ Reported With Tislelizumab in Advanced Liver Cancer
With the investigational checkpoint inhibitor tislelizumab, durable responses were achieved by some patients with previously treated advanced hepatocellular carcinoma, regardless of the number of prior lines of therapy, in the phase II RATIONALE 208 trial. These findings were presented during the...
Expert Point of View: Giuseppe Curigliano, MD, PhD
Invited discussant Giuseppe Curigliano, MD, PhD, Associate Professor of Medical Oncology at the University of Milan, Italy, and Head of the Division of Early Drug Development at the European Institute of Oncology, said the “clear” findings of KEYNOTE-5221 are “practice-changing.” However, the...
KEYNOTE-522: Neoadjuvant Pembrolizumab Improves Event-Free Survival in Triple-Negative Breast Cancer
The latest analysis of the pivotal phase III KEYNOTE-522 trial demonstrated significant improvements in clinical outcomes with pembrolizumab plus chemotherapy vs chemotherapy alone as a neoadjuvant/adjuvant treatment of triple-negative breast cancer.1 This is the first large, randomized, phase III...
Surbhi Sidana, MD, Comments on CAR T-Cell Therapy and Bispecific Antibodies Targeting Myeloma
The session’s invited discussant Surbhi Sidana, MD, Assistant Professor of Medicine, Stanford University, said CAR T-cell therapy and bispecific antibodies targeting myeloma are emerging as potentially effective options for patients with highly refractory disease. For this population of triple...
Bispecific Antibodies Advance in Relapsed or Refractory Multiple Myeloma
For the challenging population of patients with multiple myeloma who have become refractory to essentially all current treatments, new approaches are much needed. Early clinical trials data suggest bispecific antibodies may help meet this need, as suggested by studies presented at the 2021 ASCO...
Expert Point of View: Lisa Carey, MD
NEOTALA’s invited discussant, Lisa Carey, MD, the Richardson and Marilyn Jacobs Preyer Distinguished Professor in Breast Cancer Research and Deputy Director of Clinical Sciences at the University of North Carolina-Chapel Hill, saw the findings as part of a bigger trend toward reducing the use of...
Single-Agent Talazoparib Shows Activity in the Neoadjuvant Treatment of Triple-Negative Breast Cancer
For the neoadjuvant treatment of triple-negative breast cancer, the oral poly (ADP-ribose) polymerase (PARP) inhibitor talazoparib yielded promising pathologic complete response rates in the phase II single-arm NEOTALA trial presented at the 2021 ASCO Annual Meeting.1 Preoperative chemotherapy is...
Expert Point of View: Evandro de Azambuja, MD, PhD
“KAITLIN didnot meet its primary endpoint, either in the intent-to-treat or node-positive population,1 but in context with the APHINITY trial [1 year of adjuvant pertuzumab/trastuzumab plus chemotherapy],2 whose outcomes were similar at 3 years, you can appreciate that both arms did extremely...
KAITLIN Trial: No Subgroup Benefits More From T-DM1 Plus Chemotherapy for HER2-Positive Early Breast Cancer
In the phase III KAITLIN trial, replacing adjuvant taxane and trastuzumab with ado-trastuzumab emtansine (T-DM1) did not result in a significant improvement in invasive disease–free survival in the node-positive or intent-to-treat population of women with high-risk, HER2-positive early breast...
Breast Cancer in 2030: Predictions From a Breast Cancer Luminary
According to George W. Sledge, Jr, MD, FASCO, Professor of Medicine in the Division of Oncology at Stanford University Medical Center, by the beginning of the next decade, clinicians will be aided by the use of artificial intelligence (AI) in many facets of care and by the approval of a wave of new ...
Expert Point of View: Fabrice André, MD, PhD
Fabrice André, MD, PhD, Director of Research and Professor of Medical Oncology at Institut Gustave Roussy, Villejuif, France, commented on the two studies that used the MammaPrint 70-gene signature to identify patients for de-escalation or escalation of endocrine therapy.1,2 The push to...
MINDACT Trial Shows ‘Excellent’ Outcomes in Ultra-Low–Risk Breast Cancer
Patients with ultra-low–risk breast cancer, as classified by the MammaPrint 70-gene assay, had “excellent” long-term outcomes regardless of clinical risk or receipt of adjuvant therapy, a new analysis of the MINDACT trial has shown.1 In a separate study, a retrospective analysis of the National...
Expert Point of View: Amit M. Oza, MD, MBBS
Invited discussant of the FORWARD II trial,1Amit M. Oza, MD, MBBS, concluded that bevacizumab and mirvetuximab soravtansine was a “very well tolerated and effective” combination with “encouraging activity,” even in patients previously treated with bevacizumab and weekly paclitaxel. Dr. Oza is Head ...
